Willow Biosciences Inc.

WLLW

CA97111B4047

Pharmaceuticals

End-of-day quote Toronto S.E. Other stock markets 03:30:00 24/06/2024 am IST			5-day change	1st Jan Change
0.105 ^CAD	0.00%		+5.00%	+5.00%

03/06	Willow Biosciences to Raise Up to $3 Million Via Brokered Private Placement; Shares Jumped 24% on Friday	MT
03/06	Willow Biosciences Brief: Announcing Brokered Private Placement Offering To Raise Up To $3 Million	MT

Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024

May 13, 2024 at 04:41 pm IST

Willow Biosciences Inc. provided earnings guidance for the fiscal year 2024. The Company remains steadfast in its revenue expectations for Fiscal Year 2024 revenues to at least double from Fiscal Year 2023. This revenue expectation for Fiscal Year 2024 is forecast to be driven from existing programs as well as new expected programs to be signed during the year.

Latest news about Willow Biosciences Inc.

Willow Biosciences to Raise Up to $3 Million Via Brokered Private Placement; Shares Jumped 24% on Friday	03/06	MT
Willow Biosciences Brief: Announcing Brokered Private Placement Offering To Raise Up To $3 Million	03/06	MT
Willow Biosciences Inc. announced that it expects to receive CAD 3 million in funding	03/06	CI
Willow Biosciences Signs Multi-Product Development, Licensing Partnership With Laurus Lab	30/05	MT
Willow Biosciences Brief: Announcing Multi-product Development and Licensing Partnership With Laurus Lab	30/05	MT
Willow Biosciences Inc. Announces Multi-Product Development and Licensing Partnership with Laurus Labs	30/05	CI
Willow Biosciences Brief: Reiterating its Expectations of at least doubling its full year 2024 revenues, As Reports Q1 Results	13/05	MT
Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024	13/05	CI
Willow Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Willow Biosciences Narrows 2023 Loss YOY	01/04	MT
Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Willow Biosciences Announces Second Strategic Investment From Kalsec	01/03	MT
Willow Biosciences Secures Strategic Investment From Kalsec to Develop Natural Food Ingredient	21/02	MT
Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.	20/02	CI
Willow Biosciences Enters Partnership With Global Ingredient Manufacturer	31/01	MT
Willow Biosciences Inc. Announces Collaboration with Global Active Pharmaceutical Ingredient Manufacturer to Develop A More Sustainable, Cost-Effective Manufacturing Process for A Large Volume Global Market	31/01	CI
Willow Biosciences Announces Collaboration with Active Pharmaceutical Ingredient Manufacturer to Manufacture More Sustainable, Cost-Effective Manufacturing Route for Their Largest Product Sold Globally	31/01	CI
Willow Biosciences Announces Collaboration With Enterin	16/01	MT
Willow Biosciences Inc. Announces Collaboration with Enterin, Inc. to Develop Sustainable Interimates and Active Pharmaceutical Ingredients	16/01	CI
Willow Biosciences Highlights Growth Plans for 2024, Provides 2023 Highlights	10/01	MT
Willow Biosciences Brief: Says Plans For "Significant" Growth In 2024	10/01	MT
Toronto Stocks Flat; Laurentian Bank of Canada Declines on Lower 4Q Profit, Revenue	07/12	DJ
Willow Biosciences and Nasdaq-listed Biopharma Co Advancing Development Program	07/12	MT
Willow Biosciences Brief: Willow and a Nasdaq-listed biopharma company Advancing Development Program	07/12	MT
Willow Biosciences Reports Q3 Results, Provides Update	15/11	MT

Chart Willow Biosciences Inc.

Duration

Period

More charts

Company Profile

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.

Sector

Pharmaceuticals

Calendar

26/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
WILLOW BIOSCIENCES INC.	+5.00%	9.79M
CSL LIMITED	+2.46%	93.98B
SAMSUNG BIOLOGICS CO.,LTD.	-3.42%	37.69B
BIOGEN INC.	-12.43%	32.99B
UCB	+75.98%	28.27B
BIOMARIN PHARMACEUTICAL INC.	-11.70%	16.17B
INCYTE CORPORATION	+1.53%	14.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.82%	11.44B
ALTEOGEN INC.	+190.36%	10.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.07%	9.26B

Biopharmaceuticals